MarketCap
Facebook
X
TelegramOrphazyme A/S Betriebsaufwand 2011-2026 | ORPH
Betriebsaufwand Jährlich Orphazyme A/S
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| - | 336 M | 232 M | 131 M | 63.5 M | 37.1 M | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 336 M | 37.1 M | 160 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M |  USA |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
argenx SE
ARGX
|
2.27 B | $ 834.06 | 0.94 % | $ 25 B |  Niderland |
 |
Ascendis Pharma A/S
ASND
|
338 M | $ 234.24 | -0.3 % | $ 5 B |  Danmark |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.81 | 1.31 % | $ 4.42 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Atea Pharmaceuticals
AVIR
|
193 M | $ 4.66 | 1.42 % | $ 393 M | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | China |
 |
Axsome Therapeutics
AXSM
|
99.1 M | $ 167.61 | -4.09 % | $ 8.34 B | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.33 | 0.79 % | $ 8.01 B |  Australia |
 |
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
BioVie
BIVI
|
18.1 M | $ 1.25 | 0.4 % | $ 1.85 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
BioMarin Pharmaceutical
BMRN
|
1.47 B | $ 63.02 | 0.15 % | $ 12 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | USA |
 |
CASI Pharmaceuticals
CASI
|
38.9 M | $ 0.79 | 4.29 % | $ 108 M | USA |
 |
Catalyst Biosciences
CBIO
|
176 M | $ 12.71 | 10.81 % | $ 837 M | USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | Canada |
 |
Capricor Therapeutics
CAPR
|
49.3 M | $ 27.89 | 0.07 % | $ 747 M | USA |
 |
Aptose Biosciences
APTO
|
26.3 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 110.88 | 0.86 % | $ 27.2 B | Germany |
 |
Amneal Pharmaceuticals
AMRX
|
539 M | $ 14.72 | 2.08 % | $ 4.55 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | USA |
 |
Certara
CERT
|
232 M | $ 6.67 | 2.77 % | $ 1.07 B | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 9.32 | 1.25 % | $ 1.5 B | Britain |
 |
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.85 | 6.65 % | $ 472 M | Britain |